Insider Selling: Keros Therapeutics (NASDAQ:KROS) Director Sells 2,625 Shares of Stock

Keros Therapeutics, Inc. (NASDAQ:KROS) Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the completion of the sale, the director directly owned 10,958 shares of the company’s stock, valued at $117,579.34. This trade represents a 19.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Keros Therapeutics Stock Down 2.9%

Shares of KROS traded down $0.30 during midday trading on Monday, reaching $10.00. The company had a trading volume of 169,361 shares, compared to its average volume of 378,172. Keros Therapeutics, Inc. has a 1-year low of $9.79 and a 1-year high of $22.55. The stock has a market cap of $197.92 million, a PE ratio of -3.32 and a beta of 0.94. The firm has a 50 day simple moving average of $11.33 and a 200-day simple moving average of $15.15.

Keros Therapeutics (NASDAQ:KROS) last issued its earnings results on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%.The company had revenue of $0.37 million during the quarter, compared to analyst estimates of $1.93 million. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.19 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds have recently modified their holdings of the business. Western Standard LLC lifted its stake in Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after acquiring an additional 654,989 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Keros Therapeutics by 282.5% during the 4th quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after acquiring an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board acquired a new position in Keros Therapeutics during the 2nd quarter worth about $4,251,000. Caption Management LLC lifted its stake in Keros Therapeutics by 114.1% during the 2nd quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after acquiring an additional 291,997 shares in the last quarter. Finally, Qube Research & Technologies Ltd lifted its stake in Keros Therapeutics by 683.7% during the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after acquiring an additional 264,445 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have issued reports on KROS shares. Wells Fargo & Company cut their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th. Weiss Ratings cut Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th. Finally, Wall Street Zen cut Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Three equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $20.40.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.